导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.46% | 3936/4773 |
| 近一周 | -2.52% | 3988/5465 |
| 近一月 | -2.80% | 1915/5421 |
| 近一季 | -2.52% | 1404/5231 |
| 近半年 | -4.38% | 2803/4920 |
| 近一年 | -15.76% | 3775/4394 |
| 近两年 | 29.84% | 2286/2954 |
| 近三年 | 10.08% | 1752/2253 |
| 成立以来 | -33.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.55% 4669/4961 |
8.77% 2546/5312 |
- - |
- - |
| 2025 | 3.52% 3117/4813 |
-6.67% 3386/3635 |
4.15% 846/4076 |
10.85% 3233/4524 |
-3.93% 3360/4813 |
| 2024 | 28.21% 159/3463 |
-4.86% 1780/2808 |
-8.26% 2199/3014 |
43.44% 10/3129 |
2.40% 948/3463 |
| 2023 | 3.84% 258/2656 |
3.84% 1111/2280 |
-2.77% 662/2385 |
7.49% 38/2515 |
-4.31% 961/2655 |
| 2022 | -24.89% 1270/2207 |
-18.12% 1303/1919 |
2.09% 1362/2016 |
-15.10% 1216/2113 |
5.85% 428/2208 |
| 2021 | -2.38% 852/1822 |
-14.00% 1164/1255 |
6.76% 723/1330 |
4.51% 344/1466 |
1.74% 814/1822 |
| 2020 | 17.59% 762/1250 |
-9.87% 722/1022 |
8.49% 819/1060 |
18.13% 84/1152 |
- - |
| 2019 | 46.08% 141/1092 |
46.69% 12/748 |
-5.77% 478/797 |
-3.84% 741/844 |
9.89% 174/912 |
| 2018 | -22.63% 251/834 |
- - |
- - |
- - |
-0.37% 3/691 |
| 2017 | -10.62% 535/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.51% 379/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证全指证券公司指数(LOF)A VS. 长安沪深300非周期A(740101) |